Cyclophosphamide vs Carboplatin: side effects in FDA adverse event reports
At a glance
| Cyclophosphamide | Carboplatin | |
|---|---|---|
| Drug class | Alkylating Drug | Platinum-based Drug |
| Brand names | – | – |
| FAERS reports | 175,993 | 126,268 |
| Serious | 96% | 95% |
| Death outcome | 35,641 | 20,032 |
| Boxed warning | No | Yes Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriat |
Signals both drugs share
| Reaction | Cyclophosphamide | Carboplatin | Label screen (A / B) |
|---|---|---|---|
| Diffuse large b-cell lymphoma recurrent | 1,247 · PRR 166.5 | 276 · PRR 24.4 | Likely indication confounding / Not in label — unassessed |
| Diffuse large b-cell lymphoma refractory | 391 · PRR 86.5 | 133 · PRR 27.6 | Likely indication confounding / Not in label — unassessed |
| Congenital aplasia | 85 · PRR 49.3 | 50 · PRR 34.5 | Not in label — unassessed / Not in label — unassessed |
Labeled signals distinctive to Cyclophosphamide
- Cytomegalovirus infection reactivation — n=1,352, PRR 55.1 Labeled (related wording)
- Cystitis haemorrhagic — n=1,125, PRR 46.1 Labeled (related wording)
- Hepatitis b reactivation — n=791, PRR 39.3 Labeled (related wording)
- Viral haemorrhagic cystitis — n=284, PRR 80.2 Labeled (related wording)
- Secondary immunodeficiency — n=283, PRR 36.8 Labeled (related wording)
- Cystitis viral — n=177, PRR 103.7 Labeled (related wording)
- Ovarian failure — n=143, PRR 42.7 Labeled adverse reaction
- Cystitis bacterial — n=100, PRR 49.4 Labeled (related wording)
Labeled signals distinctive to Carboplatin
- Ototoxicity — n=255, PRR 26.4 Labeled adverse reaction
- Ovarian cancer metastatic — n=96, PRR 21.3 Labeled (related wording)
Common questions
Which has more reported side effects, Cyclophosphamide or Carboplatin?
Cyclophosphamide has 175,993 FAERS reports and Carboplatin 126,268. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (96% vs 95%) is a better like-for-like signal of the kind of problems reported.
Which side effects do Cyclophosphamide and Carboplatin share?
Both drugs carry disproportionality signals for diffuse large b-cell lymphoma recurrent, diffuse large b-cell lymphoma refractory, congenital aplasia. Shared signals often reflect a shared drug class or the condition both are used for.
Is Cyclophosphamide or Carboplatin safer?
FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.